417 results on '"Genge, Angela"'
Search Results
2. SF2Former: Amyotrophic Lateral Sclerosis Identification From Multi-center MRI Data Using Spatial and Frequency Fusion Transformer
3. Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study
4. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy.
5. The neurophysiological brain-fingerprint of Parkinson’s disease
6. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
7. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial
8. Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA Study.
9. Temporal and spatial progression of microstructural cerebral degeneration in ALS: A multicentre longitudinal diffusion tensor imaging study
10. Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study
11. Rare-variant and polygenic analyses of amyotrophic lateral sclerosis in the French-Canadian genome
12. Validating Automatic Diadochokinesis Analysis Methods across Dysarthria Severity and Syllable Task in Amyotrophic Lateral Sclerosis
13. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.
14. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
15. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
16. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
17. Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch
18. The value of testing for ATXN2 intermediate repeat expansions in routine clinical practice for amyotrophic lateral sclerosis
19. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials.
20. Rate of speech decline in individuals with amyotrophic lateral sclerosis
21. The C-BIG Repository: an Institution-Level Open Science Platform
22. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
23. Evaluating the Safety, Tolerability, and Pharmacokinetics of QRL-101 in Two Phase 1 Studies: QRL-101-01 in Healthy Adults and QRL-101-02 in Adults with ALS (P6-11.019)
24. QRL-201-01—A Multi-center, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis (P6-11.010)
25. Cost-effectiveness Analysis of Efgartigimod Versus Chronic Intravenous Immunoglobulin (IVIg) for Treatment of Acetylcholine Receptor Antibody Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG) in Canada (P4-11.003)
26. Dysregulation of Adipocyte Response in Amyotrophic Lateral Sclerosis: Developing the Humanized in Vitro Model System to Screen for Immuno-metabolic Molecular Signatures (P5-11.001)
27. Long-term Safety and Efficacy of Zilucoplan in Myasthenia Gravis: Additional Interim Analyses of RAISE-XT (S15.002)
28. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial
29. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
30. Harmonized standard operating procedures for administering the ALS functional rating scale-revised
31. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study
32. The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials.
33. Amyotrophic lateral sclerosis: exploring pathophysiology in the context of treatment.
34. Texture classification of MR images of the brain in ALS using M-CoHOG: A multi-center study
35. Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration
36. Phase 3, open-label, multicenter safety study of oral edaravone in patients with amyotrophic lateral sclerosis (MT-1186-A01): 48-week results
37. Biomarkers and clinical trials in ALS
38. Evaluating the safety, tolerability, and pharmacokinetics of QRL-101 in two phase 1 studies: QRL-101-01 in healthy adults and QRL-101-02 in adults with ALS
39. Long-term safety, efficacy & self-injection satisfaction with zilucoplan in myasthenia gravis: RAISE-XT interim analysis
40. QRL-201-01: A multi-center, randomized, double-blind, placebo-controlled multiple ascending dose study to evaluate the safety and tolerability of QRL-201 in amyotrophic lateral sclerosis
41. Amyotrophic lateral sclerosis: exploring pathophysiology in the context of treatment
42. Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study.
43. Speech timing and monosyllabic diadochokinesis measures in the assessment of amyotrophic lateral sclerosis in Canadian French.
44. Harmonized standard operating procedures for administering the ALS functional rating scale-revised.
45. Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis
46. Harmonized standard operating procedures for administering the ALS functional rating scale-revised
47. SF2Former: Amyotrophic lateral sclerosis identification from multi-center MRI data using spatial and frequency fusion transformer
48. Oral edaravone – Introducing a Flexible Treatment Option for Amyotrophic lateral sclerosis
49. 2603 Safety and tolerability of zilucoplan in RAISE-XT: a multicenter, open-label extension study in patients with myasthenia gravis
50. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.